Clinical trial

This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.

NCT07846358

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-11-01

PhasePHASE1 / PHASE2

Study timeline

Study start (estimated)2026-11-01Date precision: month

Registry last updated2026-09-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

RAS Mutationunresolved

Non-small Cell Lung Cancer (NSCLC)unresolved

Interventions

GFH276DRUG

with or without TislelizumabDRUG

PemetrexedDRUG · verified · RxNorm: pemetrexed

CisplatinDRUG · verified · RxNorm: cisplatin

CarboplatinDRUG · verified · RxNorm: carboplatin

Sponsors & collaborators

Genfleet Therapeutics (Shanghai) Inc.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07846358 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.